At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12 enrolled
Drug / intervention
erlotinib (Tarceva) and bexarotene (Targretin)drug
Likely dose
Erlotinib 150 mg orally once daily + bexarotene 400 mg/m2/day orally for 7–9 days prior to thoracotomyAI-extracted
Key inclusion· 3
- ✓Resectable stage I or II non-small-cell lung cancer
- ✓Prior tissue biopsy (not cytology) available for research analysis
- ✓Adequate hepatic and renal function
Key exclusion· 1
- ✕Prior chemotherapy or radiotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer
In Brief
A clinical study evaluating erlotinib (Tarceva) and bexarotene (Targretin) for Carcinoma, Non-small-cell Lung. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-small-cell Lung
CountriesUnited States
CollaboratorsLigand Pharmaceuticals, Genentech, Inc.
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2005
Enrollment StartDec 2005
Primary CompletionAug 2010
TodayJul 2026
First PostedAug 1, 2005
Enrollment StartDec 1, 2005
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 20.9 years ago
Interventions
erlotinib (Tarceva) and bexarotene (Targretin)drug
Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy